Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Lipid nanoparticles (LNPs) are promising mRNA delivery vehicles due to their biocompatibility and tunable characteristics. While current rational design approaches focus on ionizable lipids' p and zeta potential to optimize mRNA encapsulation and endosomal escape, the selection of helper lipids remains largely empirical. We propose that the lipid transition temperature (), marking the shift from the gel to the liquid crystalline phase, can guide rational helper lipid selection. Through screening 54 ionizable lipids, we identified H7T4, which displayed favorable physicochemical properties when combined with its tail variants but exhibited poor transfection efficiency. Using nano differential scanning calorimetry (nDSC) and biological small-angle X-ray scattering (BioSAXS), we found that lowering the system's by combining H7T4 (high transition temperature) with a low-transition-temperature helper lipid such as 1,2-dioleoyl--glycero-3-phosphoethanolamine (DOPE) significantly enhanced mRNA cellular uptake both and . These findings establish as a crucial parameter for a rational LNP design.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086761 | PMC |
| http://dx.doi.org/10.1021/acsami.5c06464 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Lipid-Based Nanomedicine: Pathway Specific siRNA Therapy and Optimizing Delivery for Hepatocellular Carcinoma.
Int J Nanomedicine
September 2025
Department of Pharmaceutics, Crescent School of Pharmacy, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai, Tamilnadu, India.
Hepatocellular carcinoma (HCC) is a major global health issue, ranking as the sixth most common cancer and a leading cause of cancer-related deaths worldwide. Risk factors for HCC include chronic hepatitis B and C, obesity, alcohol abuse, diabetes, and metabolic disorders. Current treatments, such as surgery, transplantation, and chemotherapy, are often ineffective in advanced stages due to tumor resistance and the inability to target key oncogenic pathways.
View Article and Find Full Text PDFAnalytical approach for identification and mechanistic insights into mRNA-lipid adduct formation.
Mol Ther Nucleic Acids
September 2025
Sanofi, 1541 Avenue Marcel Mérieux, 69280 Marcy l'Etoile, France.
Messenger ribonucleic acid (mRNA), a promising tool in vaccine and therapeutic development, is reliant on intact mRNA delivery into target cells. Given its susceptibility to degradation, ensuring its stability is crucial, necessitating rigorous quality control throughout the product life cycle. This study presents an ion-pair reverse-phase liquid chromatography method that enables rapid and direct mRNA extraction from lipid nanoparticles, facilitated by using a surfactant in the sample preparation.
View Article and Find Full Text PDFTargeting Wnt-driven metabolic adaptations in cancer: integrating glycolysis, glutaminolysis, IDO1-mediated immune evasion, and therapeutic delivery strategies.
Front Cell Dev Biol
August 2025
Department of Oncology Science, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
The Wnt pathway is an evolutionarily conserved signaling cascade that regulates a wide range of fundamental cellular processes, including proliferation, differentiation, polarity, migration, metabolism, and survival. Due to its central regulatory roles, Wnt signaling is critically involved in the pathophysiology of numerous human diseases. Aberrant activation or insufficient inhibition of this pathway has been causally linked to cancer, degenerative disorders, metabolic syndromes, and developmental abnormalities.
View Article and Find Full Text PDFReversing PAI-1 deficiency in blood using mRNA lipid nanoparticles.
Mol Ther Methods Clin Dev
September 2025
Versiti Blood Research Institute, Milwaukee, WI 53226, USA.
Plasminogen activator inhibitor-1 (PAI-1) deficiency is a rare disorder that causes moderate to severe bleeding and cardiac fibrosis, caused by mutation in the gene and no detectable circulating PAI-1 protein. There are currently no therapies that can effectively replace PAI-1 because the protein has a short half-life. An alternative approach to using recombinant protein is to endogenously increase circulating PAI-1 levels using mRNA therapy.
View Article and Find Full Text PDFLipid nanoparticles (LNPs) are widely used in drug delivery due to their low toxicity, excellent biocompatibility, and ability to facilitate endosomal escape. A critical factor influencing the in vivo behavior of LNPs is the formation of a biomolecular corona (BC) on their surface. This layer of biomolecules affects key biological processes such as targeting, absorption, distribution, metabolism, and clearance.
View Article and Find Full Text PDF